| dc.creator | Calvo M,Carlos | |
| dc.creator | Olmos C,Alfonso | |
| dc.creator | Ulloa M,Natalia | |
| dc.creator | Bustos A,Alejandra | |
| dc.creator | Toledo B,Lorena | |
| dc.creator | Durán S,Daniel | |
| dc.creator | Naveas,Rina | |
| dc.date | 2000-01-01 | |
| dc.date.accessioned | 2019-05-02T21:10:42Z | |
| dc.date.available | 2019-05-02T21:10:42Z | |
| dc.identifier | https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000100002 | |
| dc.identifier.uri | http://revistaschilenas.uchile.cl/handle/2250/81042 | |
| dc.description | Background: High density lipoproteins are an heterogeneous population of particles. Two main subpopulations have been identified, one contains Apo A-I and Apo A-II and is denominated LpA-I:A-II and another one contains only Apo A-I and is denominated LpA-I. Aim: To measure the concentrations of these particles in patients with stable coronary artery disease. Patients and Methods: Serum lipids, A-I and B apolipoproteins, LpA-I, LpA-I:A-II and LpB particles were measured in 73 men aged 33 to 82 years with angiographically documented coronary artery disease (CAD) and 33 control subjects aged 39 to 76 years. LpA-I, LpA-I:A-II and LpB were measured by a noncompetitive enzyme linked immunoassay using previously characterized monoclonal antibodies against ApoA-I, ApoA-II and apoB. Results: Patients with CAD had significantly higher mean levels of LDL cholesterol than the control group (p= 0.038). The mean concentration of LpA-I particles in patients with CAD was significantly lower (p= 0.031) than in control subjects, while the concentration of LpA-I:A-II particles was significantly higher (p=0.016). The percentage of coronary stenosis correlated negatively with LpA-I and positively with LpA-I:A-II. The best relative risk (RR) indicator in these patients was LDL-cholesterol. The relative risk increases 2.5 fold when LpA-I falls below the cut-off level. Likewise, the relative risk increases 3-fold when LpA-I:A-II raises over the cut-off level. Conclusions: Our findings indicate that the quantification of LpA-I and LpA-I:A-II particles might allow a more accurate evaluation of the CAD risk than HDL cholesterol. LpA-I might represent the antiatherogenic fraction of HDL. (Rev Méd Chile 2000; 128: 9-16) | |
| dc.format | text/html | |
| dc.language | es | |
| dc.publisher | Sociedad Médica de Santiago | |
| dc.relation | 10.4067/S0034-98872000000100002 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | Revista médica de Chile v.128 n.1 2000 | |
| dc.subject | Coronary disease | |
| dc.subject | Cholesterol | |
| dc.subject | Lipoproteins | |
| dc.subject | Lipoproteins, HDL cholesterol | |
| dc.title | Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria | |
